Abstract
As the number of adrenergic beta-blocking drugs with potential usefulness in man rapidly increases, the need to expand our knowledge of these agents also increases. An improved insight into the biological fate of these drugs is necessary to be able to understand the actions they produce, both beneficial and maybe also toxic. It is known, for example, that several beta-blocking drugs produce pharmacologically active metabolites. A metabolites of propranolol with intact beta-blocking side-chain, 4-hydroxy- propranolol, is equipotent to propranolol as a beta-blocker in animals (1) and would appear to contribute to the effects of propranolol in man (2, 3). Other metabolites of propranolol, such as the glycollic and N-desalkylated metabolites, have also been shown to possess pharmacologic activity (4–6), metabolites which would be expected to be common to beta-blocking drugs in general.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
J.D. Fritzgerald and S.R. O’Donnel, Brit. J. Pharmacol.,1971, 43, 222.
D.J. Coltart and D.J. Shand, Brit. Med. J., 1970, 3, 731.
T. Walle, E. Conradi, K. Walle, T. Fagan and T.E. Gaffney, Clin. Res., 1977, 25, 10A.
D.A. Saelens, T. Walle, P.J. Privitera, D.R. Knapp and T.E. Gaffney, J. Pharmacol. Exp. Ther., 1974, 188, 86.
D.A. Saelens, T. Walle, T.E. Gaffney and P.J. Privitera, Eur. J. Pharmacol., 1977, 42, 39.
H.R. Ing and W.E. Ormerod, J. Pharm. Pharmacol., 1952, 4, 21.
D.A. Garteiz and T. Walle, J. Pharm. Sei., 1972, 61, 1728.
T. Walle, J. Pharm. Sei., 1974, 63, 1885.
T. Walle, J. Morrison, K. Walle and E. Conradi, J. Chromatogr., 114, 351.
D.A. Saelens, T. Walle and P.J. Privitera, J. Chromatog., 123, 185.
N.-O. Bodin, Life Sci., 1974, 14, 685.
P. Borchert, P.G. Wislocki, J.A. Miller and E.C. Miller, Cancer Res., 1973, 33, 575.
T. Walle and T.E. Gaffney, J. Pharmacol. Exp. Ther., 1972, 182, 83.
G.L. Tindell, T. Walle and T.E. Gaffney, Life Sei., Part II, 11, 1029.
T. Walle, J.I. Morrison and G.L. Tindell, Res. Commun. Chem. Pathol. Pharmacol., 1974, 9, 1.
B. Åblad, M. Brogård and H. Corrodi, Acta Pharm. Suec., 1970, 7, 551.
P.G. Wislocki, “On the proximate and ultimate carcinogenic metabolites of precarcinogens: Safrole and certain N-alkyl-aminoazobenzene dyes”, Dissertation, Univ. of Wisconsin- Madison, Abstr. in Dissertation Abstracts, 1974, 36, 219-B.
W.G. Stillwell, J. Carman, L. Bell and M.G. Horning, Drug Metab. Disp., 1974, 2 , 489.
J.A. Miller and E.C. Miller, in “Biological Reactive Intermediates: Formation, toxicity and inactivation”, D.J. Jollow, J.J. Kocsis, R. Snyder and H. Vainio, Eds., Plenum Press, New York, 1977, p. 6.
T. Walle, Fed. Proceed., 1977, 36 , 961.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1978 Plenum Press, New York
About this chapter
Cite this chapter
Walle, T., Walle, K. (1978). Specific Ion Detection of Aryloxy Beta Blocking Drugs for Metabolic Fate Determinations-Applications to Alprenolol in Rats and Dogs. In: Frigerio, A. (eds) Recent Developments in Mass Spectrometry in Biochemistry and Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3991-5_3
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3991-5_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3993-9
Online ISBN: 978-1-4613-3991-5
eBook Packages: Springer Book Archive